Awakn Life Sciences (OTC:AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has entered into a global licensing agreement ...

Psychedelics R&D biotech Biomind Labs Inc. BMNDF has completed the development of a novel sublingual formulation and the first production batch for testing in its Phase 2 trial on proprietary ...

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...

Please provide your email address to receive an email when new articles are posted on . PHOENIX — Epinephrine can reach therapeutic plasma concentrations via sublingual administration, according to a ...

Please provide your email address to receive an email when new articles are posted on . Aquestive aims to submit a new drug application in the first quarter of 2025. The company hopes to launch in ...

WARREN, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address ...

Subcutaneous allergen-specific immunotherapy has long been used in allergic rhinitis and/or asthma and has been recognized to be efficacious. However, owing to the inconvenience of injection and the ...

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...

WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...

TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots This rapid inhibition is critical during suspected heart attacks, ...